Lypanosys is an innovative drug development company for the rapidly growing Dermatology market. Students passionate about biomedical science and business enterprise have the chance to learn from a company that boasts several patents.
Headquartered in Singapore, Lypanosys' drug compound LYP-010 is in the approval process with the Investigational New Drug (IND) application with the US Food and Drug Administration.
Their product is an exciting solution for the most common chronic inflammatory skin disease in children. Students will enjoy the fascinating application of biomedical science to target common medical conditions in a real-world setting.
For more information visit the official website at